European Medicines Agency and US Food and Drug Administration continue strengthening collaboration in pharmacovigilance area
21.02.2014
The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) continue strengthening collaboration in pharmacovigilance area by setting up a cluster of regular meetings which focus on medicines safety topics.
The EMA and the FDA have already set up such clusters to discuss issues related to biosimilars, medicines to treat cancer, orphan medicines, medicines for children and blood-based products.
Further information is available on the EMA webpages, or here.
